SARS-CoV-2 vaccines, along with other public health measures, have been highly efficacious in reducing infections and mortality worldwide. However, with the emergence of several variants of concern with increased transmissibility and immune-evasive properties, the SARS-CoV-2 pandemic continues to be a threat to public health. Further understanding of the development of vaccine-induced immunity, in the presence of booster and additional vaccinations and breakthrough infections, remains necessary.
The Zurich SARS-CoV-2 Vaccine Cohort study was conceived shortly after the roll-out of the first SARS-CoV-2 vaccines in the Canton of Zurich. It is an ongoing population-based longitudinal cohort study of 575 randomly selected individuals presenting for primary SARS-CoV-2 vaccination at the University of Zurich vaccination center, the reference center for the Canton of Zurich. Individuals are assessed in regular intervals up to 3 years after vaccination aiming to evaluate antibody and T cell immune responses, potential breakthrough infections, and health outcomes over time. The objectives of the study are the following:
For further information, please contact the study team via e-mail: zhcorona-impfstudie AT ebpi.uzh.ch.